Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.39, $0.03 better than the analyst estimate of $0.36. Revenue for the quarter came in at $52.5 million versus the consensus estimate of $43.1 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.